Top

BMC Cancer

Published in:

Open Access 01-12-2024 | Prostate Cancer | Research

Gut microbiota in patients with prostate cancer: a systematic review and meta-analysis

Authors: Haotian Huang, Yang Liu, Zhi Wen, Caixia Chen, Chongjian Wang, Hongyuan Li, Xuesong Yang

Published in: BMC Cancer | Issue 1/2024

Abstract

Background

Increasing evidence indicates that gut microbiota are closely related to prostate cancer. This study aims to assess the gut microbiota composition in patients with prostate cancer compared to healthy participants, thereby advancing understanding of gut microbiota's role in prostate cancer.

Methods

A systematic search was conducted across PubMed, Web of Science, and Embase databases, in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The methodological quality of included studies was evaluated using the Newcastle–Ottawa Scale (NOS), and pertinent data were analyzed. The kappa score assessed interrater agreement.

Results

This study encompassed seven research papers, involving 250 prostate cancer patients and 192 controls. The kappa was 0.93. Meta-analysis results showed that alpha-diversity of gut microbiota in prostate cancer patients was significantly lower than in the control group. In terms of gut microbiota abundance, the ratio of Proteobacteria, Bacteroidia, Clostridia, Bacteroidales, Clostridiales, Prevotellaceae, Lachnospiraceae, Prevotella, Escherichia-Shigella, Faecalibacterium, and Bacteroides was higher in prostate cancer patients. Conversely, the abundance ratio of Actinobacteria, Bacteroidetes, Firmicutes, Selenomonadales, Veillonella, and Megasphaera was higher in the control group.

Conclusion

Our study reveals differences in alpha-diversity and abundance of gut microbiota between patients with prostate cancer and controls, indicating gut microbiota dysbiosis in those with prostate cancer. However, given the limited quality and quantity of selected studies, further research is necessary to validate these findings.

Available only for authorised users

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA A Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRef

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA A Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708.CrossRef

Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. Int J Urol. 2018;25(6):524–31. https://doi.org/10.1111/iju.13593.CrossRefPubMed

Wong MC, Goggins WB, Wang HH, Fung FD, Leung C, Wong SY, Ng CF, Sung JJ. Global Incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol. 2016;70(5):862–74. https://doi.org/10.1016/j.eururo.2016.05.043.CrossRefPubMed

Wang G, Zhao D, Spring DJ, DePinho RA. Genetics and biology of prostate cancer. Genes Dev. 2018;32(17–18):1105–40. https://doi.org/10.1101/gad.315739.118.CrossRefPubMedPubMedCentral

Garrett WS. Cancer and the microbiota. Science. 2015;348(6230):80–6. https://doi.org/10.1126/science.aaa4972.ADSCrossRefPubMedPubMedCentral

Fabiani R, Minelli L, Bertarelli G, Bacci S. A Western dietary pattern increases prostate cancer risk: a systematic review and meta-analysis. Nutrients. 2016;8(10):626. https://doi.org/10.3390/nu8100626.CrossRefPubMedPubMedCentral

Massari F, Mollica V, Di Nunno V, Gatto L, Santoni M, Scarpelli M, Cimadamore A, Lopez-Beltran A, Cheng L, Battelli N, et al. The human microbiota and prostate cancer: friend or foe? Cancers (Basel). 2019;11(4):459. https://doi.org/10.3390/cancers11040459.CrossRefPubMed

Porter CM, Shrestha E, Peiffer LB, Sfanos KS. The microbiome in prostate inflammation and prostate cancer. Prostate Cancer Prostatic Dis. 2018;21(3):345–54. https://doi.org/10.1038/s41391-018-0041-1.CrossRefPubMed

10.

Banerjee S, Robertson ES: Future Perspectives: Microbiome, Cancer and Therapeutic Promise. In.; 2019: 363–389.

11.

Woo V, Alenghat T. Epigenetic regulation by gut microbiota. Gut Microbes. 2022;14(1):2022407. https://doi.org/10.1080/19490976.2021.2022407.CrossRefPubMedPubMedCentral

12.

Lacroix V, Cassard A, Mas E, Barreau F. Multi-omics analysis of gut microbiota in inflammatory bowel diseases: what benefits for diagnostic, prognostic and therapeutic tools? Int J Mol Sci. 2021;22(20):11255. https://doi.org/10.3390/ijms222011255.CrossRefPubMedPubMedCentral

13.

Morais LH. Schreiber HLt, Mazmanian SK: The gut microbiota-brain axis in behaviour and brain disorders. Nat Rev Microbiol. 2021;19(4):241–55. https://doi.org/10.1038/s41579-020-00460-0.CrossRefPubMed

14.

Hou M, Xu G, Ran M, Luo W, Wang H. APOE-ε4 carrier status and gut microbiota dysbiosis in patients with alzheimer disease. Front Neurosci. 2021;15:619051. https://doi.org/10.3389/fnins.2021.619051.CrossRefPubMedPubMedCentral

15.

Palacios T, Vitetta L, Coulson S, Madigan CD, Lam YY, Manuel R, Briskey D, Hendy C, Kim JN, Ishoey T, et al. Targeting the intestinal microbiota to prevent type 2 diabetes and enhance the effect of metformin on glycaemia: a randomised controlled pilot study. Nutrients. 2020;12(7):2041. https://doi.org/10.3390/nu12072041.CrossRefPubMedPubMedCentral

16.

Allaband C, McDonald D, Vázquez-Baeza Y, Minich JJ, Tripathi A, Brenner DA, Loomba R, Smarr L, Sandborn WJ, Schnabl B, et al. Microbiome 101: studying, analyzing, and interpreting gut microbiome data for clinicians. Clin Gastroenterol Hepatol. 2019;17(2):218–30. https://doi.org/10.1016/j.cgh.2018.09.017.CrossRefPubMed

17.

Langille MG, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, Clemente JC, Burkepile DE, Vega Thurber RL, Knight R, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol. 2013;31(9):814–21. https://doi.org/10.1038/nbt.2676.CrossRefPubMedPubMedCentral

18.

Golombos DM, Ayangbesan A, O’Malley P, Lewicki P, Barlow L, Barbieri CE, Chan C, DuLong C, Abu-Ali G, Huttenhower C, et al. The role of gut microbiome in the pathogenesis of prostate cancer: a prospective. Pilot Study Urology. 2018;111:122–8. https://doi.org/10.1016/j.urology.2017.08.039.CrossRefPubMed

19.

Fernandes A, Oliveira A, Guedes C, Fernandes R, Soares R, Barata P. Effect of radium-223 on the gut microbiota of prostate cancer patients: a pilot case series study. Curr Issues Mol Biol. 2022;44(10):4950–9. https://doi.org/10.3390/cimb44100336.CrossRefPubMedPubMedCentral

20.

McHugh ML. Interrater reliability: the kappa statistic. Biochemia medica. 2012;22(3):276–82.MathSciNetCrossRefPubMedPubMedCentral

21.

Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5. https://doi.org/10.1007/s10654-010-9491-z.CrossRefPubMed

22.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed). 2003;327(7414):557–60. https://doi.org/10.1136/bmj.327.7414.557.CrossRefPubMed

23.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed). 1997;315(7109):629–34. https://doi.org/10.1136/bmj.315.7109.629.CrossRefPubMed

24.

Alanee S, El-Zawahry A, Dynda D, Dabaja A, McVary K, Karr M, Braundmeier-Fleming A. A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis. Prostate. 2019;79(1):81–7. https://doi.org/10.1002/pros.23713.CrossRefPubMed

25.

Zhong W, Wu K, Long Z, Zhou X, Zhong C, Wang S, Lai H, Guo Y, Lv D, Lu J, et al. Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-κB-IL6-STAT3 axis. Microbiome. 2022;10(1):94. https://doi.org/10.1186/s40168-022-01289-w.CrossRefPubMedPubMedCentral

26.

Smith KS, Fruge AD, van der Pol W, Caston NE, Morrow CD, Demark-Wahnefried W, Carson TL. Gut microbial differences in breast and prostate cancer cases from two randomised controlled trials compared to matched cancer-free controls. Beneficial Microbes. 2021;12(3):239–48. https://doi.org/10.3920/bm2020.0098.CrossRefPubMedPubMedCentral

27.

Sfanos KS, Markowski MC, Peiffer LB, Ernst SE, White JR, Pienta KJ, Antonarakis ES, Ross AE. Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. Prostate Cancer Prostatic Dis. 2018;21(4):539–48. https://doi.org/10.1038/s41391-018-0061-x.CrossRefPubMedPubMedCentral

28.

Liss MA, White JR, Goros M, Gelfond J, Leach R, Johnson-Pais T, Lai Z, Rourke E, Basler J, Ankerst D, et al. Metabolic biosynthesis pathways identified from fecal microbiome associated with prostate cancer. Eur Urol. 2018;74(5):575–82. https://doi.org/10.1016/j.eururo.2018.06.033.CrossRefPubMedPubMedCentral

29.

Kalinen S, Kallonen T, Gunell M, Ettala O, Jambor I, Knaapila J, Syvänen KT, Taimen P, Poutanen M, Ohlsson C et al: Gut microbiota affects prostate cancer risk through steroid hormone biosynthesis. In.; 2021.

30.

Katz R, Ahmed MA, Safadi A, Abu Nasra W, Visoki A, Huckim M, Elias I, Nuriel-Ohayon M, Neuman H. Characterization of fecal microbiome in biopsy positive prostate cancer patients. BJUI compass. 2022;3(1):55–61. https://doi.org/10.1002/bco2.104.CrossRefPubMed

31.

Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021;19(1):55–71. https://doi.org/10.1038/s41579-020-0433-9.CrossRefPubMed

32.

Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA. 2007;104(34):13780–5. https://doi.org/10.1073/pnas.0706625104.ADSCrossRefPubMedPubMedCentral

33.

Barrett-Connor E, Garland C, McPhillips JB, Khaw KT, Wingard DL. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res. 1990;50(1):169–73.PubMed

34.

Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22(4):232–40. https://doi.org/10.3322/canjclin.22.4.232.CrossRefPubMed

35.

Baker JM, Al-Nakkash L, Herbst-Kralovetz MM. Estrogen-gut microbiome axis: physiological and clinical implications. Maturitas. 2017;103:45–53. https://doi.org/10.1016/j.maturitas.2017.06.025.CrossRefPubMed

36.

Nelles JL, Hu WY, Prins GS. Estrogen action and prostate cancer. Expert Rev Endocrinol Metab. 2011;6(3):437–51. https://doi.org/10.1586/eem.11.20.CrossRefPubMedPubMedCentral

37.

Matsushita M, Fujita K, Motooka D, Hatano K, Hata J, Nishimoto M, Banno E, Takezawa K, Fukuhara S, Kiuchi H, et al. Firmicutes in gut microbiota correlate with blood testosterone levels in elderly men. World J Men’s Health. 2022;40(3):517–25. https://doi.org/10.5534/wjmh.210190.CrossRef

38.

Kure A, Tsukimi T, Ishii C, Aw W, Obana N, Nakato G, Hirayama A, Kawano H, China T, Shimizu F, et al. Gut environment changes due to androgen deprivation therapy in patients with prostate cancer. Prostate Cancer Prostatic Dis. 2023;26(2):323–30. https://doi.org/10.1038/s41391-022-00536-3.CrossRefPubMed

39.

Pernigoni N, Guo C, Gallagher L, Yuan W, Colucci M, Troiani M, Liu L, Maraccani L, Guccini I, Migliorini D, et al. The potential role of the microbiota in prostate cancer pathogenesis and treatment. Nat Rev Urol. 2023;20(12):706–18. https://doi.org/10.1038/s41585-023-00795-2.CrossRefPubMed

40.

Zha C, Peng Z, Huang K, Tang K, Wang Q, Zhu L, Che B, Li W, Xu S, Huang T, et al. Potential role of gut microbiota in prostate cancer: immunity, metabolites, pathways of action? Front Oncol. 2023;13:1196217. https://doi.org/10.3389/fonc.2023.1196217.CrossRefPubMedPubMedCentral

41.

Zhernakova A, Kurilshikov A, Bonder MJ, Tigchelaar EF, Schirmer M, Vatanen T, Mujagic Z, Vila AV, Falony G, Vieira-Silva S, et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science. 2016;352(6285):565–9. https://doi.org/10.1126/science.aad3369.ADSCrossRefPubMedPubMedCentral

42.

Newmark HL, Heaney RP. Dairy products and prostate cancer risk. Nutr Cancer-an Int J. 2010;62(3):297–9. https://doi.org/10.1080/01635580903407221.CrossRef

43.

Punnen S, Hardin J, Cheng I, Klein EA, Witte JS. Impact of meat consumption, preparation, and mutagens on aggressive prostate cancer. PLoS ONE. 2011;6(11):e27711. https://doi.org/10.1371/journal.pone.0027711.ADSCrossRefPubMedPubMedCentral

44.

Matsushita M, Fujita K, Hayashi T, Kayama H, Motooka D, Hase H, Jingushi K, Yamamichi G, Yumiba S, Tomiyama E, et al. Gut microbiota-derived short-chain fatty acids promote prostate cancer growth via IGF1 signaling. Cancer Res. 2021;81(15):4014–26. https://doi.org/10.1158/0008-5472.Can-20-4090.CrossRefPubMed

45.

Amar J, Chabo C, Waget A, Klopp P, Vachoux C, Bermúdez-Humarán LG, Smirnova N, Bergé M, Sulpice T, Lahtinen S, et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med. 2011;3(9):559–72. https://doi.org/10.1002/emmm.201100159.CrossRefPubMedPubMedCentral

46.

Fujita K, Hayashi T, Matsushita M, Uemura M, Nonomura N. Obesity, inflammation, and prostate cancer. J Clin Med. 2019;8(2):201. https://doi.org/10.3390/jcm8020201.CrossRefPubMedPubMedCentral

47.

Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027–31. https://doi.org/10.1038/nature05414.ADSCrossRefPubMed

48.

Shin NR, Whon TW, Bae JW. Proteobacteria: microbial signature of dysbiosis in gut microbiota. Trends Biotechnol. 2015;33(9):496–503. https://doi.org/10.1016/j.tibtech.2015.06.011.CrossRefPubMed

49.

Caporaso JG, Lauber CL, Costello EK, Berg-Lyons D, Gonzalez A, Stombaugh J, Knights D, Gajer P, Ravel J, Fierer N, et al. Moving pictures of the human microbiome. Genome Biol. 2011;12(5):R50. https://doi.org/10.1186/gb-2011-12-5-r50.CrossRefPubMedPubMedCentral

50.

Brennan CA, Garrett WS. Fusobacterium nucleatum - symbiont, opportunist and oncobacterium. Nat Rev Microbiol. 2019;17(3):156–66. https://doi.org/10.1038/s41579-018-0129-6.CrossRefPubMedPubMedCentral

51.

Flemer B, Lynch DB, Brown JM, Jeffery IB, Ryan FJ, Claesson MJ, O’Riordain M, Shanahan F, O’Toole PW. Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut. 2017;66(4):633–43. https://doi.org/10.1136/gutjnl-2015-309595.CrossRefPubMed

52.

Richman EL, Kenfield SA, Stampfer MJ, Giovannucci EL, Chan JM. Egg, red meat, and poultry intake and risk of lethal prostate cancer in the prostate-specific antigen-era: incidence and survival. Cancer Prev Res (Phila). 2011;4(12):2110–21. https://doi.org/10.1158/1940-6207.Capr-11-0354.CrossRefPubMed

53.

Meyer F, Bairati I, Shadmani R, Fradet Y, Moore L. Dietary fat and prostate cancer survival. Cancer causes & control : CCC. 1999;10(4):245–51. https://doi.org/10.1023/a:1008913307947.CrossRefPubMed

54.

Nishijima S, Suda W, Oshima K, Kim SW, Hirose Y, Morita H, Hattori M. The gut microbiome of healthy Japanese and its microbial and functional uniqueness. DNA Res. 2016;23(2):125–33. https://doi.org/10.1093/dnares/dsw002.CrossRefPubMedPubMedCentral

55.

Catalona WJ. Prostate cancer screening. Med Clin North Am. 2018;102(2):199–214. https://doi.org/10.1016/j.mcna.2017.11.001.CrossRefPubMedPubMedCentral

56.

Musazadeh V, Roshanravan N, Dehghan P, Ahrabi SS. Effect of probiotics on liver enzymes in patients with non-alcoholic fatty liver disease: an umbrella of systematic review and meta-analysis. Front Nutr. 2022;9:844242. https://doi.org/10.3389/fnut.2022.844242.CrossRefPubMedPubMedCentral

57.

Keramati M, Kheirouri S, Musazadeh V, Alizadeh M. Association of high dietary acid load with the risk of cancer: a systematic review and meta-analysis of observational studies. Front Nutr. 2022;9:816797. https://doi.org/10.3389/fnut.2022.816797.CrossRefPubMedPubMedCentral

58.

Musazadeh V, Zarezadeh M, Ghalichi F, Ahrabi SS, Jamilian P, Jamilian P, Ghoreishi Z. Anti-obesity properties of probiotics; a considerable medical nutrition intervention: Findings from an umbrella meta-analysis. Eur J Pharmacol. 2022;928:175069. https://doi.org/10.1016/j.ejphar.2022.175069.CrossRefPubMed

59.

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama. 2000;283(15):2008–12. https://doi.org/10.1001/jama.283.15.2008.CrossRefPubMed

Title: Gut microbiota in patients with prostate cancer: a systematic review and meta-analysis
Authors: Haotian Huang
Yang Liu
Zhi Wen
Caixia Chen
Chongjian Wang
Hongyuan Li
Xuesong Yang
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Prostate Cancer
Prostate Cancer
Respiratory Microbiota
Published in: BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-024-12018-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Ferroptosis is a protective factor for the prognosis of cancer patients: a systematic review and meta-analysis

Circulating miR-16-5p, miR-92a-3p and miR-451a are biomarkers of lung cancer in Tunisian patients

Hypoxia-induced miR-181a-5p up-regulation reduces epirubicin sensitivity in breast cancer cells through inhibiting EPDR1/TRPC1 to activate PI3K/AKT signaling pathway

Eukaryotic initiation factor 3a promotes the development of diffuse large B-cell lymphoma through regulating cell proliferation

EMP3 as a prognostic biomarker correlates with EMT in GBM

A system review of central nervous system tumors on children in China: epidemiology and clinical characteristics

Keynote webinar | Spotlight on antibody–drug conjugates in cancer